| 601 |
24270740 | BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. | 2014 Mar |
3 |
| 602 |
24307721 | Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. | 2014 Feb 20 |
4 |
| 603 |
24311722 | Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). | 2014 Feb 20 |
2 |
| 604 |
24332241 | Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. | 2014 Jan |
1 |
| 605 |
24338680 | The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies. | 2014 Mar |
3 |
| 606 |
24357428 | Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. | 2014 Mar |
3 |
| 607 |
24415539 | Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. | 2014 Mar 20 |
2 |
| 608 |
24445187 | Ibrutinib and indolent B-cell lymphomas. | 2014 Aug |
2 |
| 609 |
24472371 | Ibrutinib for B cell malignancies. | 2014 Jan 28 |
4 |
| 610 |
24481980 | Ibrutinib in B-cell Lymphomas. | 2014 Jun |
2 |
| 611 |
24598688 | [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies]. | 2014 Feb |
1 |
| 612 |
24612681 | Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. | 2014 Jun |
2 |
| 613 |
24659631 | Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. | 2014 May 22 |
1 |
| 614 |
24693884 | Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. | 2014 Apr 3 |
2 |
| 615 |
24697238 | The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. | 2014 Jul |
4 |
| 616 |
24756799 | Ibrutinib. | 2014 |
1 |
| 617 |
24759210 | Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor. | 2014 Apr 24 |
1 |
| 618 |
24778403 | Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. | 2014 Jun 10 |
1 |
| 619 |
24829205 | Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. | 2014 Jun 26 |
3 |
| 620 |
24869598 | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. | 2014 Jun 12 |
8 |
| 621 |
24895895 | Bruton's TK inhibitors: structural insights and evolution of clinical candidates. | 2014 Apr |
1 |
| 622 |
24918646 | Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. | 2014 Apr |
3 |
| 623 |
24957109 | Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. | 2014 Sep |
6 |
| 624 |
24970801 | Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. | 2014 Jul 15 |
1 |
| 625 |
25026208 | Ibrutinib treatment of CLL: the cancer fights back. | 2014 Jul 14 |
2 |
| 626 |
25042202 | Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. | 2014 Aug |
1 |
| 627 |
25081321 | Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. | 2014 Dec |
1 |
| 628 |
25082755 | Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. | 2014 Sep |
9 |
| 629 |
25150798 | Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. | 2014 Sep |
2 |
| 630 |
25158606 | Ibrutinib for the treatment of mantle cell lymphoma. | 2014 Oct |
1 |
| 631 |
25258342 | IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. | 2014 Dec 4 |
1 |
| 632 |
25294819 | Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. | 2014 Oct 30 |
2 |
| 633 |
25360238 | Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. | 2014 Aug |
2 |
| 634 |
25361916 | Ibrutinib for the treatment of mantle cell lymphoma. | 2014 Nov 1 |
2 |
| 635 |
25696845 | BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. | 2014 Dec 5 |
1 |
| 636 |
22975686 | BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. | 2013 Jan |
3 |
| 637 |
23045577 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. | 2013 Jan 1 |
4 |
| 638 |
23296407 | Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. | 2013 Mar |
3 |
| 639 |
23360303 | The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. | 2013 Apr |
4 |
| 640 |
23672610 | Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. | 2013 Aug |
2 |
| 641 |
23754751 | Dual phosphorylation of Btk by Akt/protein kinase b provides docking for 14-3-3ζ, regulates shuttling, and attenuates both tonic and induced signaling in B cells. | 2013 Aug |
2 |
| 642 |
23763320 | [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas]. | 2013 |
1 |
| 643 |
23782157 | Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. | 2013 Aug 8 |
2 |
| 644 |
23782158 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. | 2013 Jul 4 |
1 |
| 645 |
23940282 | Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. | 2013 Oct 3 |
3 |
| 646 |
23954894 | Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. | 2013 Oct 10 |
1 |
| 647 |
23958373 | Ibrutinib and novel BTK inhibitors in clinical development. | 2013 Aug 19 |
1 |
| 648 |
23962569 | Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. | 2013 Oct |
3 |
| 649 |
24014301 | Towards targeted therapy of chronic lymphocytic leukemia. | 2013 |
1 |
| 650 |
24083545 | The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia. | 2013 Oct |
2 |